Nephrology
Conference Coverage
SGLT2 inhibitors: No benefit or harm in hospitalized COVID-19
“I think the most important take-home message here is that the use of these medications appears to be safe even in really acutely ill hospitalized...
News
FDA approves new drug, sotagliflozin, for heart failure
“It will be a reasonably tall task for sotagliflozin to come from behind and be disruptive in a space where there are already two well-established...
Latest News
CKD Screening in all U.S. adults found cost effective
Modeling showed screening for and treating chronic kidney disease in U.S. adults was cost effective now that SGLT2 inhibitors are available.
Latest News
Promising new antibiotic emerges for treating UTIs
It would be the first new treatment in 20 years for UTIs, which affect more than half of women at least sometime in their lives.
News
Kidney function may help docs pick antiplatelet mix after stroke
Ticagrelor–aspirin compared with clopidogrel-aspirin reduced risk for recurrent stroke with no substantial increase in severe or moderate bleeding...
Conference Coverage
Terlipressin decreases need for renal replacement therapy in liver transplant recipients
The drug restores renal blood flow and reverses hepatorenal syndrome type 1 in some patients.
News
Islet transplants in type 1 diabetes durable up to 8 years
Long-term insulin independence and safety is seen with islet-cell transplant in patients with severe hypoglycemia at baseline.
News
‘Too good to be true’? Ultrasound safely treats kidney stones
The results of limited patient discomfort and stone motion in 66% of treated patients seem “almost too good to be true.”
Conference Coverage
No invasive strategy benefit at 5 years in ISCHEMIA-CKD extension study
The trial speaks to the lofty high-risk status of patients with CAD. ‘You’re seeing in a group of patients, with largely preserved EF but advanced...
Conference Coverage
Albuminuria linked to higher CVD risk in diabetes
An analysis of more than 74,000 Danish people with type 2 diabetes showed an elevated CVD event rate in those with albuminuria.